Cluenex
Log inStart free
All stocks · Healthcare · Health Care Equipment

Edwards Lifesciences EW

Edwards Lifesciences scores excellent on business quality (7.6 of 10). Here is why, in plain words, and what our sealed record shows.

Last price$85.21Oct 9, 2026
Business qualityExcellent
Next earningsNov 4, 2026, after the close
Insiders, 90 daysSelling

Why it matters

  1. What Edwards Lifesciences does

    Edwards Lifesciences makes structural heart medical devices, generating revenue by selling heart valves and repair products to hospitals and cardiac surgeons.

  2. What it does best

    Edwards dominates transcatheter aortic heart valves, posting a gross margin of 77.8% that beats peers like Abbott at 56.8%. This edge relies on decades of clinical data and hospital switching costs.

  3. The main risk

    Regulatory hurdles and clinical trial delays threaten its specialized device pipeline, directly impacting the new product rollouts needed to sustain its premium market position.

Quality, check by check

Scored against its own industry, from company filings.

ProfitabilityFair

Operating margin stands at 28.3%, supported by top quartile sector performance. This high margin profile means profitability expands efficiently with scale.

MoatStrong

Switching costs form its moat, locking in cardiac surgeons who rely on its proven devices. Its gross margin ranks in the top quartile of its sector at 79th percentile.

GrowthSteady

Revenue grew 11.5% to $6.5B, accelerating from prior years as core heart valve demand holds steady across global hospital networks.

Financial healthStrong

With $4.2B in cash and a debt-to-equity ratio of 0.1, the balance sheet is pristine. Free cash flow reached $1.4B, showing the business is getting stronger.

Insiders

Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.

5 sold $4.4M outside pre-planned sales.

Our sealed record on EW

Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.

The first sealed verdicts appear here on Oct 11, 2026.

Questions

Is EW a good business?

Edwards Lifesciences scores excellent on the Cluenex quality check (7.6 of 10), measured against its own industry. Profitability is fair, moat strong, growth steady and financial health strong.

Are insiders buying EW?

In the last 90 days of SEC Form 4 filings: 5 sold $4.4M outside pre-planned sales.

When does EW report earnings?

Nov 4, 2026, after the close.

For members

See EW today

  • Today's verdict on EW, and why
  • Fair value with cautious, base and optimistic cases
  • The exact price that would change the verdict
  • Which stocks each signal names, the night it fires
Open in Cluenex Free to start. First month of Core free.

Cite this page: Cluenex, “Edwards Lifesciences (EW)”, https://cluenex.com/stocks/ew/, data as of Oct 10, 2026.